The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got ...

Eli Lilly is in advanced talks to acquire Ventyx Biosciences, which is developing pills for autoimmune conditions, for more ...

Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

Biopharma industry zeal for obesity therapeutics does not appear to be dying down any time soon, with Eli Lilly and Co. entering a $1.3 billion deal with Nimbus Therapeutics LLC for a new small ...

Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive worldwide license ...

Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases. Nimbus, an ...

Privately-held Boston, USA-based Nimbus Therapeutics today announced it has entered into a multi-year research collaboration ...

Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases.

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it ...

Shares of Alumis Inc. (NASDAQ:ALMS) were selling for $16.93, up $8.62, or 103%, having traded as high as $22.30 on positive top-line results from the phase III Onward1 and Onward2 trials with ...

Global leader in memory modules and flash storage, ADATA Technology Co., Ltd. will present its latest breakthroughs at CES ...